Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis

Results from PHOENIX 1

Phoebe Rich, M. Bourcier, H. Sofen, S. Fakharzadeh, Y. Wasfi, Y. Wang, U. Kerkmann, P. D. Ghislain, Y. Poulin

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background Most patients with psoriasis have nail changes, and treating nail psoriasis is challenging. Objectives To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. Methods Patients received ustekinumab 45 mg or 90 mg, or placebo at weeks 0 and 4. Ustekinumab-randomized patients continued maintenance dosing every 12 weeks, while patients receiving placebo crossed over to receive ustekinumab 45 mg or 90 mg at weeks 12/16 followed by dosing every 12 weeks. At week 40, initial responders [those with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index (PASI 75)] were rerandomized either to continue maintenance dosing or to withdraw from treatment. Nail involvement was evaluated using the Nail Psoriasis Severity Index (NAPSI) on a target fingernail, Nail Physician's Global Assessment (Nail PGA) and mean number of nails involved. Results Of 766 randomized patients, 545 (71·1%) had nail psoriasis. At week 24, the percentage improvement from baseline NAPSI score was 46·5% (ustekinumab 45 mg) and 48·7% (ustekinumab 90 mg). Percentage improvements in NAPSI ranged from 29·7% (PASI < 50) to 57·3% (PASI ≥ 90). Mean NAPSI scores improved from 4·5 at baseline to 2·4 at week 24 (45 mg) and from 4·4 to 2·2 (90 mg). Nail PGA scores and the mean number of psoriatic nails improved by week 24. Further improvement was observed for all end points among initial responders continuing maintenance treatment through week 52. Conclusions Ustekinumab significantly improves nail psoriasis, and improvements continue over time until up to 1 year of treatment in those receiving maintenance treatment. What's already known about this topic? The majority of patients with moderate-to-severe psoriasis have nail manifestations, for which limited therapies are available. What does this study add? Beyond the recognized benefit to the skin in psoriasis, ustekinumab significantly improves nail psoriasis over time. Both nail and skin manifestations of psoriasis should be considered when choosing treatment.

Original languageEnglish (US)
Pages (from-to)398-407
Number of pages10
JournalBritish Journal of Dermatology
Volume170
Issue number2
DOIs
StatePublished - Feb 1 2014

Fingerprint

Nail Diseases
Nails
Psoriasis
Ustekinumab
Therapeutics
Placebos
Maintenance

ASJC Scopus subject areas

  • Dermatology

Cite this

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis : Results from PHOENIX 1. / Rich, Phoebe; Bourcier, M.; Sofen, H.; Fakharzadeh, S.; Wasfi, Y.; Wang, Y.; Kerkmann, U.; Ghislain, P. D.; Poulin, Y.

In: British Journal of Dermatology, Vol. 170, No. 2, 01.02.2014, p. 398-407.

Research output: Contribution to journalArticle

Rich, P, Bourcier, M, Sofen, H, Fakharzadeh, S, Wasfi, Y, Wang, Y, Kerkmann, U, Ghislain, PD & Poulin, Y 2014, 'Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: Results from PHOENIX 1', British Journal of Dermatology, vol. 170, no. 2, pp. 398-407. https://doi.org/10.1111/bjd.12632
Rich, Phoebe ; Bourcier, M. ; Sofen, H. ; Fakharzadeh, S. ; Wasfi, Y. ; Wang, Y. ; Kerkmann, U. ; Ghislain, P. D. ; Poulin, Y. / Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis : Results from PHOENIX 1. In: British Journal of Dermatology. 2014 ; Vol. 170, No. 2. pp. 398-407.
@article{d3cc3868347849938ac3ad42f7263bcf,
title = "Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: Results from PHOENIX 1",
abstract = "Background Most patients with psoriasis have nail changes, and treating nail psoriasis is challenging. Objectives To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. Methods Patients received ustekinumab 45 mg or 90 mg, or placebo at weeks 0 and 4. Ustekinumab-randomized patients continued maintenance dosing every 12 weeks, while patients receiving placebo crossed over to receive ustekinumab 45 mg or 90 mg at weeks 12/16 followed by dosing every 12 weeks. At week 40, initial responders [those with ≥ 75{\%} improvement from baseline in Psoriasis Area and Severity Index (PASI 75)] were rerandomized either to continue maintenance dosing or to withdraw from treatment. Nail involvement was evaluated using the Nail Psoriasis Severity Index (NAPSI) on a target fingernail, Nail Physician's Global Assessment (Nail PGA) and mean number of nails involved. Results Of 766 randomized patients, 545 (71·1{\%}) had nail psoriasis. At week 24, the percentage improvement from baseline NAPSI score was 46·5{\%} (ustekinumab 45 mg) and 48·7{\%} (ustekinumab 90 mg). Percentage improvements in NAPSI ranged from 29·7{\%} (PASI < 50) to 57·3{\%} (PASI ≥ 90). Mean NAPSI scores improved from 4·5 at baseline to 2·4 at week 24 (45 mg) and from 4·4 to 2·2 (90 mg). Nail PGA scores and the mean number of psoriatic nails improved by week 24. Further improvement was observed for all end points among initial responders continuing maintenance treatment through week 52. Conclusions Ustekinumab significantly improves nail psoriasis, and improvements continue over time until up to 1 year of treatment in those receiving maintenance treatment. What's already known about this topic? The majority of patients with moderate-to-severe psoriasis have nail manifestations, for which limited therapies are available. What does this study add? Beyond the recognized benefit to the skin in psoriasis, ustekinumab significantly improves nail psoriasis over time. Both nail and skin manifestations of psoriasis should be considered when choosing treatment.",
author = "Phoebe Rich and M. Bourcier and H. Sofen and S. Fakharzadeh and Y. Wasfi and Y. Wang and U. Kerkmann and Ghislain, {P. D.} and Y. Poulin",
year = "2014",
month = "2",
day = "1",
doi = "10.1111/bjd.12632",
language = "English (US)",
volume = "170",
pages = "398--407",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis

T2 - Results from PHOENIX 1

AU - Rich, Phoebe

AU - Bourcier, M.

AU - Sofen, H.

AU - Fakharzadeh, S.

AU - Wasfi, Y.

AU - Wang, Y.

AU - Kerkmann, U.

AU - Ghislain, P. D.

AU - Poulin, Y.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background Most patients with psoriasis have nail changes, and treating nail psoriasis is challenging. Objectives To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. Methods Patients received ustekinumab 45 mg or 90 mg, or placebo at weeks 0 and 4. Ustekinumab-randomized patients continued maintenance dosing every 12 weeks, while patients receiving placebo crossed over to receive ustekinumab 45 mg or 90 mg at weeks 12/16 followed by dosing every 12 weeks. At week 40, initial responders [those with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index (PASI 75)] were rerandomized either to continue maintenance dosing or to withdraw from treatment. Nail involvement was evaluated using the Nail Psoriasis Severity Index (NAPSI) on a target fingernail, Nail Physician's Global Assessment (Nail PGA) and mean number of nails involved. Results Of 766 randomized patients, 545 (71·1%) had nail psoriasis. At week 24, the percentage improvement from baseline NAPSI score was 46·5% (ustekinumab 45 mg) and 48·7% (ustekinumab 90 mg). Percentage improvements in NAPSI ranged from 29·7% (PASI < 50) to 57·3% (PASI ≥ 90). Mean NAPSI scores improved from 4·5 at baseline to 2·4 at week 24 (45 mg) and from 4·4 to 2·2 (90 mg). Nail PGA scores and the mean number of psoriatic nails improved by week 24. Further improvement was observed for all end points among initial responders continuing maintenance treatment through week 52. Conclusions Ustekinumab significantly improves nail psoriasis, and improvements continue over time until up to 1 year of treatment in those receiving maintenance treatment. What's already known about this topic? The majority of patients with moderate-to-severe psoriasis have nail manifestations, for which limited therapies are available. What does this study add? Beyond the recognized benefit to the skin in psoriasis, ustekinumab significantly improves nail psoriasis over time. Both nail and skin manifestations of psoriasis should be considered when choosing treatment.

AB - Background Most patients with psoriasis have nail changes, and treating nail psoriasis is challenging. Objectives To assess improvement in fingernail psoriasis with ustekinumab treatment in the PHOENIX 1 trial. Methods Patients received ustekinumab 45 mg or 90 mg, or placebo at weeks 0 and 4. Ustekinumab-randomized patients continued maintenance dosing every 12 weeks, while patients receiving placebo crossed over to receive ustekinumab 45 mg or 90 mg at weeks 12/16 followed by dosing every 12 weeks. At week 40, initial responders [those with ≥ 75% improvement from baseline in Psoriasis Area and Severity Index (PASI 75)] were rerandomized either to continue maintenance dosing or to withdraw from treatment. Nail involvement was evaluated using the Nail Psoriasis Severity Index (NAPSI) on a target fingernail, Nail Physician's Global Assessment (Nail PGA) and mean number of nails involved. Results Of 766 randomized patients, 545 (71·1%) had nail psoriasis. At week 24, the percentage improvement from baseline NAPSI score was 46·5% (ustekinumab 45 mg) and 48·7% (ustekinumab 90 mg). Percentage improvements in NAPSI ranged from 29·7% (PASI < 50) to 57·3% (PASI ≥ 90). Mean NAPSI scores improved from 4·5 at baseline to 2·4 at week 24 (45 mg) and from 4·4 to 2·2 (90 mg). Nail PGA scores and the mean number of psoriatic nails improved by week 24. Further improvement was observed for all end points among initial responders continuing maintenance treatment through week 52. Conclusions Ustekinumab significantly improves nail psoriasis, and improvements continue over time until up to 1 year of treatment in those receiving maintenance treatment. What's already known about this topic? The majority of patients with moderate-to-severe psoriasis have nail manifestations, for which limited therapies are available. What does this study add? Beyond the recognized benefit to the skin in psoriasis, ustekinumab significantly improves nail psoriasis over time. Both nail and skin manifestations of psoriasis should be considered when choosing treatment.

UR - http://www.scopus.com/inward/record.url?scp=84894274228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894274228&partnerID=8YFLogxK

U2 - 10.1111/bjd.12632

DO - 10.1111/bjd.12632

M3 - Article

VL - 170

SP - 398

EP - 407

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -